This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hims & Hers Stock to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
HIMS' second-quarter 2025 results are likely to benefit from subscriber momentum and digital care tools.
Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +130.43% and +7.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare
by Debanjana Dey
HIMS is transforming digital healthcare with AI-driven care, a booming subscriber base, and new tech leadership.
Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of +5.00% and +1.25%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
by Zacks Equity Research
Hims & Hers benefits from strong product demand and subscriber growth ahead of second-quarter 2025 earnings, fueled by weight loss and specialty care uptake.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $58.68, indicating a +1.79% shift from the previous trading day.
HIMS vs. TDOC: Which Direct-to-Consumer Health Stock Wins Now?
by Debanjana Dey
Hims & Hers and Teladoc Health are reshaping virtual care, but which has the edge in earnings growth and strategic expansion? Let's see.
Hims & Hers Health, Inc. (HIMS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Hims & Hers Health, Teladoc Health and American Well
by Zacks Equity Research
HIMS accelerates global growth with ZAVA buyout, Canadian launch, and soaring EPS estimates pointing to 177.8% upside.
Hims & Hers Paves the Way for Global Digital Health Expansion
by Debanjana Dey
HIMS accelerates its global push with the ZAVA acquisition and a planned Canada launch targeting affordable obesity care.
Here's Why Hims & Hers Health, Inc. (HIMS) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $47.6, signifying a -5.52% move from its prior day's close.
Top Analyst Reports for Philip Morris, McDonald's & Texas Instruments
by Mark Vickery
Walmart's investments in supply chain, store remodels, and automation are fueling growth across its U.S. and international segments.
ECL Unveils ReadyDose Cleaning Program for Southeast Asian Restaurants
by Zacks Equity Research
Ecolab rolls out ReadyDose, a tablet-based cleaning solution to help Southeast Asian restaurants cut waste and boost hygiene.
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than simple ROE calculation? Tap AllianceBernstein (AB), Mama's Creations Inc. (MAMA) and Hims & Hers Health (HIMS).
All You Need to Know About Hims & Hers Health (HIMS) Rating Upgrade to Strong Buy
by Zacks Equity Research
Hims & Hers Health (HIMS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ISRG's Vessel Sealer Curved for da Vinci Systems Gets FDA Approval
by Zacks Equity Research
Intuitive Surgical wins FDA nod for its Vessel Sealer Curved, boosting the da Vinci system's precision and multifunctional capabilities.
Hims & Hers Stock Surges 90.4% in 3 Months: What's Fueling the Rally?
by Debanjana Dey
HIMS benefits from strong online revenue, subscriber growth, and global expansion moves to fuel its health platform momentum. However, challenges may hurt performance.
Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) reached $50.46 at the closing of the latest trading day, reflecting a -3.02% change compared to its last close.
Hims & Hers Health and DXC Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
HIMS rebounds on GLP-1 growth and rising earnings estimates, while DXC slumps amid falling sales and eroding investor confidence.
Bull of the Day: Hims & Hers Health (HIMS)
by Ethan Feller
Hims & Hers Health stock continues to be a market leader even amid controversy
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
by Zacks Equity Research
NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.